Dr. J. Craig Venter Joins Pattern Computer Advisory Board

REDMOND, W.A., Mar. 09, 2021 – Pattern Computer® Inc. is pleased to announce that Dr. J. Craig Venter, a well-known geneticist, biochemist, and businessman, is joining the Pattern Computer, Inc. (PCI) Advisory Board.

In 1984, while working at the National Institutes of Health, Dr. Venter developed Expressed Sequence Tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using his innovative, new whole genome shotgun technique. Using this new approach Dr Venter’s team went on to sequence numerous pathogen genomes, the Drosophilia genome and the first human genome (announced at the White House in 2000 with President Clinton). Dr Venter and his team also constructed the first synthetic cell.

Currently, Dr. Venter is Founder, Chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 150 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics.

Dr. Venter is the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Science, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology.

“Together with our whole team, I am extremely excited to have Craig Venter on board, both as our most recent addition to the Pattern Computer Advisory Board, and as a Major Purchaser investor. Craig brings to Pattern a proven record of knowing where the puck will be next, as Gretzky put it, and, more importantly, knowing the answers ahead of time. There are few people in the world with these attributes, and I have no doubt Pattern and JCVI will both benefit from this step forward. Craig’s addition also brings us one step closer to having the most advanced commercial team in bio and genetics ,” said Mark R. Anderson, CEO of Pattern Computer.

Leveraging PCI’s novel technology advancements in hardware, software and advanced mathematics, the PCI team is developing a root cause understanding of how interactions between multiple genes lead to cancers that today are considered difficult to impossible to treat. These challenging cancers develop in some cases due to individual gene modification, but in many cases, multiple reinforcing genetic mutations are involved.

“I am excited to be joining the Advisory Board of Pattern Computer. Mark Anderson and his team are creating some of the most interesting analytical approaches in the world today. PCI’s innovations are leading to novel discoveries in the complex interactions among individual genes and, more interestingly, among multiple genes and groups of genes. The PCI focus on driving innovations in analytical approaches related to developing a better understanding of inter gene activity aligns with my long-term personal interests and that of the team at JCVI,” said Dr. Venter.

About Pattern Computer

Pattern Computer, a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.

While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.


 Denyse Hudson -

 360.298.0658 -